Quick Take
Y-mAbs Therapeutics (YMAB) intends to raise $80 million in an IPO of its common stock, according to an amended registration statement.
The company is advancing a pipeline of antibody-based immunotherapy treatments for various cancers.
YMAB has a deep collaboration and partnership with Memorial Sloan Kettering Cancer Center and promising Phase 1/2 results for its lead candidates so far.
Company & Technology
New York-based YMAB was founded in 2014 to discovers and develops antibody-based therapeutic products for the treatment of cancer.
Management is headed by CEO and Director Claus Juan Møller